| Literature DB >> 30115068 |
Elizabeth Fragopoulou1, Lamprini Gavriil, Chrysa Argyrou, Ioannis Malagaris, Maria Choleva, Smaragdi Antonopoulou, Georgia Afxentiou, Eleana Nikolaou.
Abstract
BACKGROUND: Excessive oxidative stress may impair bio-molecules and cellular function. Multi antioxidant supplementation is thought to be more effective than a single antioxidant probably through the synergistic or complementary action of natural substances that could enhance the prospective effect.Entities:
Keywords: Aloe vera; Anti-oxidants; DNA oxidation; Plant extracts; Protein oxidation; Vitamins
Mesh:
Substances:
Year: 2018 PMID: 30115068 PMCID: PMC6097198 DOI: 10.1186/s12944-018-0836-z
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1Study flow chart
Daily energy expenditure, nutrient and food groups’ intake before intervention
| Placebo | Supplement |
| |
|---|---|---|---|
| Total energy intake (Kcal) | 2000 ± 450 | 1991 ± 402 | 0.9 |
| Carbohydrates (g) | 215.0 ± 49.2 | 195.3 ± 49.9 | 0.1 |
| Proteins (g) | 75.6 ± 22.2 | 77.1 ± 15.5 | 0.7 |
| Lipids (g) | 84.8 ± 21.6 | 91.0 ± 23.4 | 0.3 |
| SFA (g) | 26.3 ± 6.6 | 27.2 ± 7.3 | 0.6 |
| MUFA (g) | 38.1 ± 13.3 | 43.2 ± 13.2 | 0.1 |
| PUFA (g) | 11.6 ± 4.6 | 12.1 ± 4.3 | 0.6 |
| Fiber (g) | 18.2 ± 6.8 | 17.1 ± 8.2 | 0.5 |
| Alcohol | 0.58 (0.0–1.45) | 0.95 (0.45–1.82) | 0.1 |
| Fruits (servings/day) | 1.00 (0.04–1.86) | 0.58 (0.09–1.67) | 0.5 |
| Vegetables (servings/day) | 1.65 ± 1.51 | 2.06 ± 1.35 | 0.2 |
| Dairy total fat (servings/day) | 2.09 ± 1.25 | 2.11 ± 1.16 | 0.9 |
| Dairy low fat (servings/day) | 0.25(0.00–0.82) | 0.33 (0.00–1.00) | 0.2 |
| Red meet (servings/day) | 1.03 ± 0.88 | 1.11 ± 0.95 | 0.7 |
| Products of red meet (servings/day) | 0.94 ± 0.92 | 0.67 ± 0.75 | 0.2 |
| Chicken/turkey (servings/day) | 0.30 (0.00–0.67) | 0.27 (0.00–0.59) | 0.7 |
| Fish (servings/day) | 0.00 (0.00–0.67) | 0.00 (0.00–0.66) | 0.6 |
| Whole grain (servings/day) | 0.08(0.09–1.17) | 0.67 (0.00–2.2) | 0.4 |
| Refined grain (servings/day) | 5.01 ± 2.7 | 4.99 ± 2.38 | 0.9 |
| Legumes (servings/day) | 0.00 (0.00–0.67) | 0.00 (0.00–0.33) | 0.7 |
| Olive oil (servings/day) | 2.00 (1.75–2.00) | 2.00(2.00–2.00) | 0.6 |
| Junk Food (servings/day) | 0.33 (0.00–0.62) | 0.33 (0.00–0.67) | 0.8 |
| Physical Activity Levels | 1.50 ± 0.19 | 1.43 ± 0.18 | 0.2 |
Intake levels were estimated from 3 days dietary intake using the 24-h recall method. Data are presented as means ± SD for normally distributed variables and as median (lower-upper quartile (25th -75th) for skewed variables t-test or Mann-Whitney test was used for the comparisons respectively
Basic clinical and anthropometric characteristics of participants before intervention
| Placebo ( | Supplement ( | p | |
|---|---|---|---|
| Age (years) | 32.9 ± 5.6 | 34.9 ± 5.8 | 0.2 |
| Gender, (%male) | 64.3 | 73.3 | 0.5 |
| Body mass index (kg/m2) | 26.6 ± 2.9 | 26.0 ± 1.9 | 0.6 |
| Current smokers (%) | 75.0 | 53.3 | 0.1 |
| Systolic blood pressure (mm Hg) | 126.9 ± 10.2 | 122.7 ± 10.4 | 0.08 |
| Diastolic blood pressure (mm Hg) | 78.5 ± 8.8 | 74.4 ± 8.5 | 0.1 |
| WBC (103/μL) | 5.7 ± 1.4 | 6.24 ± 1.3 | 0.2 |
| RBC (106/μL | 4.4 ± 1.4 | 4.54 ± 1.3 | 0.7 |
| PLT 103/μL | 224.0 ± 59.1 | 240.64 ± 32.4 | 0.2 |
| Hb (g/L) | 14.6 ± 2.7 | 15.14 ± 1.3 | 0.5 |
| Ht (%) | 40.9 ± 4.2 | 40.34 ± 4.0 | 0.5 |
| Glucose (mmol/L) | 5.31 ± 0.56 | 5.62 ± 0.71 | 0.08 |
| Cholesterol (mmol/L) | 4.85 ± 1.11 | 5.20 ± 1.09 | 0.2 |
| HDL-cholesterol (mmol/L) | 1.27 ± 0.36 | 1.19 ± 0.4 | 0.4 |
| LDL-cholesterol (mmol/L) | 3.20 ± 1.13 | 3.57 ± 1.13 | 0.2 |
| Triacylglycerols (mmol/L) | 0.82 ± 0.44 | 1.04 ± 0.73 | 0.2 |
| Uric acid (mmol/L) | 0.28 ± 0.07 | 0.27 ± 0.07 | 0.6 |
Data are presented as means ± SD for normally distributed variables or as relative frequencies (%) for categorical variables t-test or chi-square was used for the comparisons respectively
Levels of oxidative stress markers of participants before intervention
| Placebo ( | Supplement ( |
| |
|---|---|---|---|
| LagTime (min) | 56.0 ± 20.4 | 53.0 ± 12.6 | 0.5 |
| Isoprostane(ng/mmol creatinine) | 75.1 (47.5—261.1) | 96.1 (52.1–236.7) | 0.4 |
| TBARS (μM) | 5.21 ± 1.22 | 5.05 ± 1.59 | 0.6 |
| oxLDL (μg/mL) | 1.23 (0.681–2.35) | 1.54 (1.01–2.31) | 0.1 |
| 8-hydroxy-2΄- deoxyguanosine (μg/mmol creatinine) | 10.5 (5.23–21.4) | 12.0 (8.36–16.5) | 0.9 |
| Protein Carbonyls (nmol/mg protein | 81.1 (61.3–93.7) | 95.3 (70.6–133.1) | 0.04 |
| Gpx activity (U/mL) | 0.0826 (0.0734–0.0964) | 0.0911 (0.0774–0.0911) | 0.4 |
| SOD activity (U/mg) | 16.8 (9.64–27.1) | 18.2 (11.2–25.5) | 0.6 |
Data are presented as means ± SD for normally distributed variables and as median (lower-upper quartile (25th -75th) for skewed variables, t-test or Mann-Whitney test was used for the comparisons respectively
Levels of basic anthropometric and biochemical markers during intervention
| Time (weeks) | 0 | 4 | 8 | ptrial | |
|---|---|---|---|---|---|
| BMI (kg/m2) | Placebo ( | 26.6 ± 2.9 | 26.7 ± 3.0 | 26.7 ± 3.0 | 0.7 |
| Supplement ( | 27.0 ± 2.0 | 26.8 ± 2.0 | 26.8 ± 1.9 | ||
| Systolic blood pressure (mm Hg) | Placebo ( | 78.5 ± 8.8 | 74.0 ± 8.8 | 72.4 ± 8.2 | 0.8 |
| Supplement ( | 74.5 ± 8.5 | 75.3 ± 8.6 | 73.3 ± 8.4 | ||
| Diastolic blood pressure (mm Hg) | Placebo ( | 126.9 ± 10.2 | 120.2 ± 12.7 | 119.2 ± 9.7 | 0.8 |
| Supplement ( | 122.7 ± 10.5 | 117.4 ± 10.4 | 120.0 ± 7.4 | ||
| Glucose (mmol/L) | Placebo ( | 5.31 ± 0.56 | 5,27 ± 0.54 | 5.32 ± 0.63 | 0.09 |
| Supplement ( | 5.62 ± 0.71 | 5.63 ± 0.73 | 5.46 ± 0.69 | ||
| Cholesterol (mmol/L) | Placebo ( | 4.85 ± 1.11 | 4.71 ± 0.98 | 4.69 ± 1.07 | 0.1 |
| Supplement ( | 5.20 ± 1.09 | 5.10 ± 1.04 | 5.07 ± 1.11 | ||
| HDL-chol (mmol/L) | Placebo ( | 1.27 ± 0.37 | 1.23 ± 0.35 | 1.25 ± 0.35 | 0.4 |
| Supplement ( | 1.19 ± 0,41 | 1.17 ± 0.37 | 1.16 ± 0.37 | ||
| LDL-chol (mmol/L) | Placebo ( | 3.20 ± 1.13 | 3.12 ± 1.06 | 3.06 ± 1.17 | 0.1 |
| Supplement ( | 3.58 ± 1.18 | 3.53 ± 1.16 | 3.49 ± 1.18 | ||
| Triacylglycerols (mmol/L) | Placebo ( | 0.82 ± 0.44 | 0.83 ± 0.54 | 0.81 ± 0.46 | 0.1 |
| Supplement ( | 1.04 ± 0.73 | 0.97 ± 0.68 | 1.06 ± 0.78 | ||
| Uric acid (mmol/L) | Placebo ( | 0.28 ± 0.07 | 0.27 ± 0.07 | 0.28 ± 0.07 | 0.5 |
| Supplement ( | 0.27 ± 0.07 | 0.27 ± 0.06 | 0.27 ± 0.07 |
Data are presented as means ± SD for normally distributed variables. Repeated measures ANOVA was used for the comparisons
% change of oxidative stress markers during intervention
| Placebo ( | Supplement ( | P4–4b | PPlc | |||
|---|---|---|---|---|---|---|
| % of baseline levels | 4 week | 8 week | 4 week | 8 week | ||
| LagTime (min)a | 99.9 ± 17.2 | 98.9 ± 12.4 | 96.1 ± 17.1 | 102.2 ± 19.8 | ||
| Isoprostane (ng/mmol) | 102.7 (83.5–136.1) | 129.8# (100.2–186.9) | 90.3 (58.3–112.1) | 79.0 (45.6–122.9) | 0.05 0.003 | 0.005 0.3 |
| oxLDL (μg/mL) | 97.1 (89.0 0–104.4) | 100.5 (87.7–110.0) | 100.3 (91.9–112.5) | 101.7 (89.2–112.1) | 0.5 0.1 | 0.2 0.8 |
| TBARS (μΜ)a | 107.1 ± 27.4 | 100.3 ± 25.5 | 100.0 ± 26.7 | 104.3 ± 31.8 | ||
| 8-hydroxy-2΄-deoxyguanosine (μg/mmol) | 96.1 (83.8–128.8) | 102.8 (88.9–145.2) | 85.2,# (60.9–101.8) | 72.3# (45.2–102.6) | 0.02 0.000 | 0.4 0.003 |
| Protein Carbonyls (nmol/mg protein) | 112.8 (91.6–120.5) | 104.5 (91.5–118.1) | 83.3# (71.7–102.3) | 81.3# (61.7–100.6) | 0.000 0.001 | 0.3 0.003 |
| Gpx activity (U/mL) | 95.8 (87.6–116.7) | 94.7 (74.8–115.4) | 100.0 (87.6–115.3) | 102.9 (88.2–117.5) | 0.8 0.1 | 0.3 0.9 |
| SOD activity (U/mg protein) | 106.4 (75.0–160.4) | 88.1 (66.7–151).7 | 63.6# |(42.8–127.4) | 71.3 (50.4–126.8) | 0.01 0.2 | 0.7 0.008 |
Data are presented as means ± SD for normally distributed variables and as median (lower-upper quartile (25th -75th) for skewed variables
aFor normally distributed variables repeated measures ANOVA was used for the comparisons (All p’s > 0.05, result section)
bFor skewed variables Mann-Whitney two independent test was used for the comparison of Supplement vs Palcebo at 4 or 8 weeks
cFriedman’s 2-way ANOVA by ranks was used for the estimation of time effect in placebo or Supplement trial, #P < 0.05 pairwise comparison vs 0 week of Friedman’s 2-way ANOVA by ranks